Clinical Trial Update: A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

This document reports on an ongoing Phase 2/Phase 3 clinical trial evaluating cidabenamine plus azacitidine to prevent post-transplant progression in high-risk …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Cidabenamine (cidabenamine)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Peripheral T Cell Lymphoma | Phase 2, Phase 3 | Status: RECRUITING